mTOR Signaling Combined with Cancer Stem Cell Markers as a Survival Predictor in Stage II Colorectal Cancer
Open Access
- 1 January 2020
- journal article
- research article
- Published by XMLink in Yonsei Medical Journal
- Vol. 61 (7) , 572-578
Abstract
Chang JY, et al. Yonsei Med J. 2020 Jul;61(7):572-578. https://doi.org/10.3349/ymj.2020.61.7.572Keywords
Funding Information
- National Research Foundation of Korea (2013R1A1A2010733)
- Korea Health Industry Development Institute (HI14C1324)
- Yonsei University College of Medicine (6-2018-0059)
This publication has 39 references indexed in Scilit:
- A distinct role for Lgr5+ stem cells in primary and metastatic colon cancerNature, 2017
- Visualization and targeting of LGR5+ human colon cancer stem cellsNature, 2017
- Role of Stem Cells in Colorectal Cancer Progression and Prognostic and Predictive Characteristics of Stem Cell Markers in Colorectal CancerCurrent Stem Cell Research & Therapy, 2016
- Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastasesInternational Journal of Oncology, 2015
- Immunohistochemical Detection of Cancer Stem Cell Related Markers CD44 and CD133 in Metastatic Colorectal Cancer PatientsBioMed Research International, 2014
- Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancerBritish Journal of Cancer, 2010
- Prognostic Significance of the Cancer Stem Cell Markers CD133, CD44, and CD166 in Colorectal CancerCancer Investigation, 2009
- EphB receptor activity suppresses colorectal cancer progressionNature, 2005
- THE WNT SIGNALING PATHWAY IN DEVELOPMENT AND DISEASEAnnual Review of Cell and Developmental Biology, 2004
- Stem cells, cancer, and cancer stem cellsNature, 2001